Last reviewed · How we verify
MEROPENEM
MEROPENEM is a drug. It is currently FDA-approved (first approved 1996).
Meropenem is a small molecule inhibitor of bacterial penicillin-binding protein. It is used to treat various bacterial infections, including those caused by Enterobacteriaceae and resistant to cephalosporins, such as bloodstream infections and acute pyelonephritis.
At a glance
| Generic name | MEROPENEM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
Common side effects
- Diarrhea
- Nausea/Vomiting
- Headache
- Inflammation at the injection site
- Rash
- Sepsis
- Constipation
- Apnea
- Shock
- Pruritus
- Injection site reaction
- Phlebitis/Thrombophlebitis
Serious adverse events
- Gastrointestinal hemorrhage
- Hepatic failure
- Heart failure
- Heart arrest
- Myocardial infarction
- Pulmonary embolus
- Seizure
- Kidney failure
- Melena
- Hallucinations
Key clinical trials
- Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) (PHASE4)
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- SYN-004 Safety and Tolerability in Allo-HCT Subjects (PHASE1, PHASE2)
- A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (PHASE2)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP (PHASE3)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEROPENEM CI brief — competitive landscape report
- MEROPENEM updates RSS · CI watch RSS
Frequently asked questions about MEROPENEM
What is MEROPENEM?
When was MEROPENEM approved?
What development phase is MEROPENEM in?
What are the side effects of MEROPENEM?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing